|
|
维兰特罗关键中间体及有关物质的高效液相色谱分析方法优化
|
Abstract:
维兰特罗是一种治疗慢性阻塞性肺病(COPD)的β2受体激动剂，其起效作用快、持续时间长、耐受性好而备受关注。2-(2,2-二甲基-4H-1,3-苯并二氧杂环己烯-6-基)-2-羰基乙基氨基甲酸叔丁酯是合成维兰特罗的关键中间体之一，德信佳生物医药公司开发了一种绿色合成工艺，该路线经由五步反应，共涉及5个中间产物，即中间体1、2、3、4、5。本研究拟建立关键中间体5 (2-(2,2-二甲基-4H-1,3-苯并二氧杂环己烯-6-基)-2-羰基乙基氨基甲酸酯)及其有关物质(或杂质)的HPLC分析方法，通过流动相组成及比例、检测波长等条件筛选与优化，中间体1、2、4、5主成分及有关物质可以实现有效分离；利用上述建立的HPLC方法，对两批次中间体5产品的有关物质进行分析，并采用峰面积归一化法计算含量。它们均检测到三个有关物质，其总和低于1.5%，该研究为后续关键中间体及原料药中有关物质的制备分离、结构推测及定量分析提供了方法参考。
Vilanterol, a β2 receptor agonist inhibiting chronic obstructive pulmonary disease (COPD), has been respected for rapid effect, long duration and good tolerance. 2-(2,2-dimethyl-4H-1,3-benzodioxane heterocyclohexene-6-yl)-2-carbonyl ethyl carbamate is one of the key intermediates of vilanterol, which has developed by Dexinjia Biopharm Co., Ltd. The green preparation route is divided into five-step reactions involving five intermediates, namely intermediate 1, 2, 3, 4, 5. In this study, the HPLC analysis method of intermediate 5 (2-(2,2-dimethyl-4H-1,3-benzodioxane heterocyclohex-ene-6-yl)-2-carbonyl ethyl carbamate) and its related substances (or impurities) was optimized mainly through the composition and proportion of mobile phase and detection wavelength. As a result, the intermediate 1, 2, 4, 5 and related substances can be effectively separated. Using the es-tablished HPLC method, the related substances of two batches of intermediate 5 were analyzed, three major related substances were detected and the total content was less than 1.5% according to the peak area normalization. These investigations provided experimental methods for the further preparation, structural speculation and quantitative analysis of related substances in the key in-termediates and raw drugs of vilanterol.
| [1] | Slack, R.J., Barrett, V.J., Morrison, V.S., Sturton, R.G., Emmons, A.J., Ford, A. and JKnowles, R.G. (2013) In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action. The Journal of Pharmacology and Experimental Therapeutics, 344, 218-230.
https://doi.org/10.1124/jpet.112.198481 |
| [2] | L？tvall, J., Bateman, E.D., Bleecker, E.R., Busse, W.W., Woodcock, A., Follows, R., Lim, J., Stone, S., Jacques, L. and Haumann B. (2012) 24-h Duration of the Novel LABA Vilanterol Trifenatate in Asthma Patients Treated with Inhaled Corticosteroids. The European Respiratory Journal, 40, 570-579. https://doi.org/10.1183/09031936.00121411 |
| [3] | Box, P.C., Coe, D.M., Looker, B.E., Procopiou, P.A. and Mann, I.S. (2003) Phenethanolamine Derivatives for Treatment of Respiratory Diseases. WO Patent No. 2003024439. |
| [4] | Procopiou, P.A., Barrett, V.J., Bevan, N.J., Biggadike, K., Box, P.C., Butchers, P.R., Coe, D.M., Conroy, R., Emmons, A., Ford, A.J., Holmes, D.S., Horsely, H., Kerr, F., Anne-Marie, L., Looker, B.E., Mann, I.S., Mclay, I.M., Morrison, V.S., Mutch, P.J., Smith, C.E. and Tomlin, P. (2010) Synthesis and Structure-Activity Relation-ships of Long-Acting β2 Adrenergic Receptor Agonists Incorporating Metabolic Inactivation: An Antedrug Approach. Journal of Medicinal Chemistry, 53, 4522-4530. https://doi.org/10.1021/jm100326d |
| [5] | Dammalapati, V.L.N.R., Mudduluru, H.K. and Aduri, R. (2014) An Improved Process for the Preparation of VilanterolL and Intermediates Thereof. WO Patent No. 2014041565. |
| [6] | 季宗德, 杨玉雷, 蒋慧娟,莫利英, 朱雪焱[P]. 中国专利, 105646285A. 2016-06-08. |
| [7] | 王卓春. 维兰特罗关键中间体合成新方法[J]. 广东化工, 2018, 45(5): 9. |
| [8] | 郑庚修, 汪崇文, 高令峰, 张启龙, 卢伟阳. 一种在混合溶剂中合成维兰特罗中间体的方法[P]. 中国专利, 109574817A. 2019-04-05. |
| [9] | 王红磊, 许坤, 张启龙, 汪崇文, 林建华. 一种固体酸催化合成维兰特罗中间体的方法[P]. 中国专利, 109574982A. 2019-04-05. |
| [10] | Munster-Muller, S., Zimmermann, R. and Putz, M. (2018) A Novel Impuri-ty-Profiling Workflow with the Combination of Flash-Chromatography, UHPLC-MS and Multivariate Data Analysis for Highly Pure Drugs: A Study on the Synthetic Cannabinoid MDMB-CHMICA. Analytical Chemistry, 90, 10559-10567.
https://doi.org/10.1021/acs.analchem.8b02679 |
| [11] | 龚珊. 色谱技术在原料药杂质分析中的应用[J]. 化工设计通讯, 2019, 45(6): 200-201. |
| [12] | 王术兰, 唐克慧, 张春然, 王宇驰, 祝淳君, 王瑛瑛. 梯度洗脱HPLC测定奥达特罗的有关物质[J]. 中国新药杂志, 2018, 27(4): 483-488. |
